1194769-56-6Relevant articles and documents
Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy
Boshta, Nader M.,Bua, Silvia,Lee, Sang-Yong,Mirza, Salahuddin,Namasivayam, Vigneshwaran,Perotti, Arianna,Supuran, Claudiu T.,Müller, Christa E.
, p. 1187 - 1206 (2021/10/27)
Nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) catalyzes the hydrolysis of extracellular nucleotides. It is expressed by immune cells and some carcinomas,e.g.of kidney and colon. Together with ecto-5′-nucleotidase (CD73), NPP3 produces immunosuppres
4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES
-
Page/Page column 96; 102-103, (2014/02/16)
The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
-
Paragraph 0569-0572; 0610, (2014/03/21)
The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.